Catalyst Pharmaceuticals Files 8-K

Ticker: CPRX · Form: 8-K · Filed: 2024-03-13T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, SEC Filing, Financials

Related Tickers: CPRX

TL;DR

Catalyst Pharma filed an 8-K, standard procedure, no major news yet.

AI Summary

Catalyst Pharmaceuticals, Inc. filed an 8-K on March 13, 2024, to report other events and financial statements. The filing does not contain specific details on new events or financial figures but serves as a notification of these items.

Why It Matters

This filing indicates Catalyst Pharmaceuticals is updating its public disclosures with the SEC, which is a standard procedural requirement for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a routine procedural update and does not disclose any new material risks or events.

Key Players & Entities

FAQ

What specific events are being reported under 'Other Events'?

The provided text of the 8-K filing does not specify the details of the 'Other Events' beyond stating that this section is being reported.

What financial statements are being filed with this 8-K?

The filing indicates that 'Financial Statements and Exhibits' are being filed, but the specific content or period covered by these statements is not detailed in the provided text.

What is the Central Index Key (CIK) for Catalyst Pharmaceuticals, Inc.?

The CIK for Catalyst Pharmaceuticals, Inc. is 0001369568.

When was Catalyst Pharmaceuticals, Inc. incorporated and in which state?

Catalyst Pharmaceuticals, Inc. was incorporated in Delaware.

What is the Standard Industrial Classification (SIC) code for Catalyst Pharmaceuticals, Inc.?

The SIC code for Catalyst Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001193125-24-066931.txt : 20240313 0001193125-24-066931.hdr.sgml : 20240313 20240313170100 ACCESSION NUMBER: 0001193125-24-066931 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240313 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240313 DATE AS OF CHANGE: 20240313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 24746834 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d798971d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2024-03-13 2024-03-13     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 13, 2024     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   355 Alhambra Circle   Suite 801   Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events On March 13, 2024, the Company issued a press release announcing the U.S. commercial launch of AGAMREE ® (vamorolone) oral suspension 40 mg/mL for the treatment of Duchenne Muscular Dystrophy in patients aged two years and older. Following the U.S. Food and Drug Administration approval on October 26, 2023, AGAMREE ® is now available by p

View on Read The Filing